CF PharmTech, Inc. (02652.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 2.83B

MomentumView details →

1D Return

−6.78%

YTD Return

−69.44%

RSI (14)

22.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 2.83B

RSI (14)

22.9

MomentumView details →

1D Return

−6.78%

YTD Return

−69.44%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−HKD 0.00

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Next earningsMar 3, 2027 →

Latest newsMore news →

Changfeng Pharmaceutical reported interim results for the six months ended June 2026, with revenue of RMB 210 million, up 2.1% year-on-year, gross profit of RMB 161 million, up 3.2%, and a net loss widening to RMB 10.51 million from RMB 1.23 million in the prior-year period, with no dividend declared.4d ago

Similar companies

ST交昂600530.SH Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.01349.HK Supernus Pharmaceuticals, Inc.SUPN 益佰制药600594.SH Bausch Health Companies Inc.BHC HUTCHMED (China) LimitedHCM Find similar companies →

Latest newsMore news →

Changfeng Pharmaceutical reported interim results for the six months ended June 2026, with revenue of RMB 210 million, up 2.1% year-on-year, gross profit of RMB 161 million, up 3.2%, and a net loss widening to RMB 10.51 million from RMB 1.23 million in the prior-year period, with no dividend declared.4d ago